Get Quotes none
Home / Healthcare / Urinary Tract Infection Therapeutics

Urinary Tract Infection Therapeutics Market – by Age Group (Adults, Elderly, and Children), by Indication (Uncomplicated, Recurrent, Complicated, and Catheter Associated), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and by Drug Type (Quinolones, Azoles & Amphotericin B, Aminoglycoside, Penicillin & Combinations, Cephalosporin, Nitrofurans, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019–2027

  • Published On : Sep-2019
  • Total Pages : 110
  • Report Code : FAF-75
  • Base Year : 2018
  • Format :
REPORT SUMMARY
TABLE OF CONTENT
REQUEST SAMPLE

Industry Insights

The report covers a forecast and an analysis of the urinary tract infection therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the urinary tract infection therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the urinary tract infection therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the urinary tract infection therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the urinary tract infection therapeutics market by segmenting it based on age group, indication, distribution channel, drug type, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The major growth driver of the urinary tract infection therapeutics market is the escalating incidences of UTI infections. As women have shorter urethras, they are more at risk of being infected than men. The market for urinary tract infection therapeutics is also driven by the growing elderly population, particularly above 60 and above, across the world.
The age group segment of the market comprises adults, elderly, and children. Based on indication, the market includes uncomplicated, complicated, catheter-associated, and recurrent. By distribution channel, the market is categorized into e-commerce, hospital pharmacies, and retail pharmacies. On the basis of drug type, the market is fragmented into Nitrofurans, Azoles & Amphotericin B, Cephalosporin, Quinolones, Penicillin & Combinations, Aminoglycoside, and others.

Key players operating in the urinary tract infection therapeutics market are Zavante Therapeutics, Urigen, Shionogi, Novo Nordisk, Mylan, MerLion Pharmaceuticals, MediciNova, Lipella Pharmaceuticals, Dr. Reddy’s Laboratories, Bayer, Cipla, AstraZeneca, Aquinox, ALLERGAN, Achaogen, C.H. Boehringer Sohn, F. Hoffmann-La Roche, Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Novartis, GlaxoSmithKline, and Johnson & Johnson, among others.

Table of Content

  • CHAPTER 1. Executive Summary 26
  •  
  • CHAPTER 2. Urinary Tract Infection Therapeutics market – Age Group Analysis 28
    • 2.1. Global Urinary Tract Infection Therapeutics Market – Age Group Overview 28
    • 2.2. Global Urinary Tract Infection Therapeutics Market Share, by Age Group, 2018 & 2025 (USD Million) 28
    • 2.3. Adults 30
    • 2.3.1. Global Adults Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)   30
    • 2.4. Elderly 31
    • 2.4.1. Global Elderly Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  31
    • 2.5. Children 32
    • 2.5.1. Global Children Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  32
  •  
  • CHAPTER 3. Urinary Tract Infection Therapeutics market – Indication Analysis 32
    • 3.1. Global Urinary Tract Infection Therapeutics Market – Indication Overview 32
    • 3.2. Global Urinary Tract Infection Therapeutics Market Share, by Indication, 2018 & 2025 (USD Million) 33
    • 3.3. Uncomplicated UTI 34
    • 3.3.1. Global Uncomplicated UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 34
    • 3.4. Recurrent UTI 35
    • 3.4.1. Global Recurrent UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  35
    • 3.5. Complicated UTI 36
    • 3.5.1. Global Complicated UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 36
    • 3.6. CA (Catheter Associated) UTI 37
    • 3.6.1. Global CA (Catheter Associated) UTI Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 37
  •  
  • CHAPTER 4. Urinary Tract Infection Therapeutics market – Drug Type Analysis 37
    • 4.1. Global Urinary Tract Infection Therapeutics Market – Drug Type Overview 37
    • 4.2. Global Urinary Tract Infection Therapeutics Market Share, by Drug Type, 2018 & 2025 (USD Million) 38
    • 4.3. Quinolones 40
    • 4.3.1. Global Quinolones Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  40
    • 4.4. Azoles & Amphotericin B 41
    • 4.4.1. Global Azoles & Amphotericin B Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 41
    • 4.5. Aminoglycoside 42
    • 4.5.1. Global Aminoglycoside Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 42
    • 4.6. Penicillin & Combinations 43
    • 4.6.1. Global Penicillin & Combinations Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 43
    • 4.7. Cephalosporin 44
    • 4.7.1. Global Cephalosporin Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  44
    • 4.8. Nitrofurans 45
    • 4.8.1. Global Nitrofurans Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  45
    • 4.9. Others 46
    • 4.9.1. Global Others Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  46
  •  
  • CHAPTER 5. Urinary Tract Infection Therapeutics market – Distribution Channel Analysis 46
    • 5.1. Global Urinary Tract Infection Therapeutics Market – Distribution Channel Overview 46
    • 5.2. Global Urinary Tract Infection Therapeutics Market Share, by Distribution Channel, 2018 & 2025 (USD Million) 47
    • 5.3. Hospital Pharmacies 48
    • 5.3.1. Global Hospital Pharmacies Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 48
    • 5.4. Retail Pharmacies 49
    • 5.4.1. Global Retail Pharmacies Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million) 49
    • 5.5. E-commerce 50
    • 5.5.1. Global E-commerce Urinary Tract Infection Therapeutics Market, 2016-2026 (USD Million)  50
  •  
  • CHAPTER 6. Urinary Tract Infection Therapeutics market – Regional Analysis 51
    • 6.1. Global Urinary Tract Infection Therapeutics Market Regional Overview 51
    • 6.2. Global Urinary Tract Infection Therapeutics Market Share, by Region, 2018 & 2025 (Value) 51
    • 6.3. North America 53
    • 6.3.1. North America Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026  53
    • 6.3.2. North America Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 53
    • 6.3.3. North America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026  55
    • 6.3.3.1. North America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 55
    • 6.3.4. North America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026  56
    • 6.3.4.1. North America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 56
    • 6.3.5. North America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026  57
    • 6.3.5.1. North America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 57
    • 6.3.6. North America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 58
    • 6.3.6.1. North America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 58
    • 6.3.7. U.S.  59
    • 6.3.7.1. U.S. Market size and forecast, 2016-2026 (USD Million) 59
    • 6.3.8. Rest of North America 60
    • 6.3.8.1. Rest of North America Market size and forecast, 2016-2026 (USD Million) 60
    • 6.4. Europe 61
    • 6.4.1. Europe Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 61
    • 6.4.2. Europe Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million)  61
    • 6.4.3. Europe Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 63
    • 6.4.3.1. Europe Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 63
    • 6.4.4. Europe Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 64
    • 6.4.4.1. Europe Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 64
    • 6.4.5. Europe Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 65
    • 6.4.5.1. Europe Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 65
    • 6.4.6. Europe Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026  66
    • 6.4.6.1. Europe Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 66
    • 6.4.7. Germany  67
    • 6.4.7.1. Germany Market size and forecast, 2016-2026 (USD Million) 67
    • 6.4.8. France  68
    • 6.4.8.1. France Market size and forecast, 2016-2026 (USD Million) 68
    • 6.4.9. U.K.  69
    • 6.4.9.1. U.K. Market size and forecast, 2016-2026 (USD Million) 69
    • 6.4.10. Italy  70
    • 6.4.10.1. Italy Market size and forecast, 2016-2026 (USD Million) 70
    • 6.4.11. Spain  71
    • 6.4.11.1. Spain Market size and forecast, 2016-2026 (USD Million) 71
    • 6.4.12. Rest of Europe 72
    • 6.4.12.1. Rest of Europe Market size and forecast, 2016-2026 (USD Million) 72
    • 6.5. Asia Pacific 73
    • 6.5.1. Asia Pacific Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026  73
    • 6.5.2. Asia Pacific Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 73
    • 6.5.3. Asia Pacific Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026  75
    • 6.5.3.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 75
    • 6.5.4. Asia Pacific Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026   76
    • 6.5.4.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 76
    • 6.5.5. Asia Pacific Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026   77
    • 6.5.5.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 77
    • 6.5.6. Asia Pacific Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026  78
    • 6.5.6.1. Asia Pacific Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 78
    • 6.5.7. China  79
    • 6.5.7.1. China Market size and forecast, 2016-2026 (USD Million) 79
    • 6.5.8. Japan  80
    • 6.5.8.1. Japan Market size and forecast, 2016-2026 (USD Million) 80
    • 6.5.9. India  81
    • 6.5.9.1. India Market size and forecast, 2016-2026 (USD Million) 81
    • 6.5.10. South-East Asia 82
    • 6.5.10.1. South-East Asia Market size and forecast, 2016-2026 (USD Million) 82
    • 6.5.11. Rest of Asia Pacific 83
    • 6.5.11.1. Rest of Asia Pacific Market size and forecast, 2016-2026 (USD Million) 83
    • 6.6. Latin America 84
    • 6.6.1. Latin America Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026  84
    • 6.6.2. Latin America Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 84
    • 6.6.3. Latin America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026  86
    • 6.6.3.1. Latin America Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 86
    • 6.6.4. Latin America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026  87
    • 6.6.4.1. Latin America Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 87
    • 6.6.5. Latin America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026  88
    • 6.6.5.1. Latin America Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 88
    • 6.6.6. Latin America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026  89
    • 6.6.6.1. Latin America Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 89
    • 6.6.7. Brazil  90
    • 6.6.7.1. Brazil Market size and forecast, 2016-2026 (USD Million) 90
    • 6.6.8. Rest of Latin America 91
    • 6.6.8.1. Rest of Latin America Market size and forecast, 2016-2026 (USD Million) 91
    • 6.7. The Middle-East and Africa 92
    • 6.7.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market size and forecast, 2016-2026 92
    • 6.7.2. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Country, 2018 & 2025 (USD Million) 92
    • 6.7.3. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 94
    • 6.7.3.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Age Group, 2016-2026 (USD Million) 94
    • 6.7.4. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 95
    • 6.7.4.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Indication, 2016-2026 (USD Million) 95
    • 6.7.5. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 96
    • 6.7.5.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Drug Type, 2016-2026 (USD Million) 96
    • 6.7.6. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 97
    • 6.7.6.1. The Middle-East and Africa Urinary Tract Infection Therapeutics Market, by Distribution Channel, 2016-2026 (USD Million) 97
    • 6.7.7. GCC Countries 98
    • 6.7.7.1. GCC Countries Market size and forecast, 2016-2026 (USD Million) 98
    • 6.7.8. South Africa 99
    • 6.7.8.1. South Africa Market size and forecast, 2016-2026 (USD Million) 99
    • 6.7.9. Rest of Middle-East Africa 100
    • 6.7.9.1. Rest of Middle-East Africa Market size and forecast, 2016-2026 (USD Million) 100
  •  
  • CHAPTER 7. Urinary Tract Infection Therapeutics market – Competitive Landscape 101
    • 7.1. Competitor Market Share – Revenue 101
    • 7.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players 103
    • 7.3. Strategic Development 104
    • 7.3.1. Acquisitions and Mergers 104
    • 7.3.2. New Products 104
    • 7.3.3. Research & Development Activities 104
  •  
  • CHAPTER 8. Company Profiles 105
    • 8.1. Johnson & Johnson Services, Inc. 105
    • 8.1.1. Company Overview 105
    • 8.1.2. Johnson & Johnson Services, Inc. Revenue and Gross Margin 105
    • 8.1.3. Product portfolio 106
    • 8.1.4. Recent initiatives 107
    • 8.2. GlaxoSmithKline 107
    • 8.2.1. Company Overview 107
    • 8.2.2. GlaxoSmithKline Revenue and Gross Margin 107
    • 8.2.3. Product portfolio 108
    • 8.2.4. Recent initiatives 109
    • 8.3. Novartis AG 109
    • 8.3.1. Company Overview 109
    • 8.3.2. Novartis AG Revenue and Gross Margin 109
    • 8.3.3. Product portfolio 110
    • 8.3.4. Recent initiatives 111
    • 8.4. Teva Pharmaceutical Industries Ltd. 111
    • 8.4.1. Company Overview 111
    • 8.4.2. Teva Pharmaceutical Industries Ltd. Revenue and Gross Margin 111
    • 8.4.3. Product portfolio 112
    • 8.4.4. Recent initiatives 113
    • 8.5. Sun Pharmaceutical Industries Ltd. 113
    • 8.5.1. Company Overview 113
    • 8.5.2. Sun Pharmaceutical Industries Ltd. Revenue and Gross Margin 113
    • 8.5.3. Product portfolio 114
    • 8.5.4. Recent initiatives 115
    • 8.6. Pfizer Inc. 115
    • 8.6.1. Company Overview 115
    • 8.6.2. Pfizer Inc. Revenue and Gross Margin 115
    • 8.6.3. Product portfolio 116
    • 8.6.4. Recent initiatives 117
    • 8.7. F. Hoffmann-La Roche Ltd 117
    • 8.7.1. Company Overview 117
    • 8.7.2. F. Hoffmann-La Roche Ltd Revenue and Gross Margin 117
    • 8.7.3. Product portfolio 118
    • 8.7.4. Recent initiatives 119
    • 8.8. C.H. Boehringer Sohn AG & Co.KG 119
    • 8.8.1. Company Overview 119
    • 8.8.2. C.H. Boehringer Sohn AG & Co.KG Revenue and Gross Margin 119
    • 8.8.3. Product portfolio 120
    • 8.8.4. Recent initiatives 121
    • 8.9. Achaogen, Inc. 121
    • 8.9.1. Company Overview 121
    • 8.9.2. Achaogen, Inc. Revenue and Gross Margin 121
    • 8.9.3. Product portfolio 122
    • 8.9.4. Recent initiatives 123
    • 8.10. ALLERGAN 123
    • 8.10.1. Company Overview 123
    • 8.10.2. ALLERGAN Revenue and Gross Margin 123
    • 8.10.3. Product portfolio 124
    • 8.10.4. Recent initiatives 125
    • 8.11. Aquinox 125
    • 8.11.1. Company Overview 125
    • 8.11.2. Aquinox Revenue and Gross Margin 125
    • 8.11.3. Product portfolio 126
    • 8.11.4. Recent initiatives 127
    • 8.12. AstraZeneca 127
    • 8.12.1. Company Overview 127
    • 8.12.2. AstraZeneca Revenue and Gross Margin 127
    • 8.12.3. Product portfolio 128
    • 8.12.4. Recent initiatives 129
    • 8.13. Cipla Inc. 129
    • 8.13.1. Company Overview 129
    • 8.13.2. Cipla Inc. Revenue and Gross Margin 129
    • 8.13.3. Product portfolio 130
    • 8.13.4. Recent initiatives 131
    • 8.14. Bayer AG 131
    • 8.14.1. Company Overview 131
    • 8.14.2. Bayer AG Revenue and Gross Margin 131
    • 8.14.3. Product portfolio 132
    • 8.14.4. Recent initiatives 133
    • 8.15. Dr. Reddy's Laboratories Ltd. 133
    • 8.15.1. Company Overview 133
    • 8.15.2. Dr. Reddy's Laboratories Ltd. Revenue and Gross Margin 133
    • 8.15.3. Product portfolio 134
    • 8.15.4. Recent initiatives 135
    • 8.16. Lipella Pharmaceuticals Inc. 135
    • 8.16.1. Company Overview 135
    • 8.16.2. Lipella Pharmaceuticals Inc. Revenue and Gross Margin 135
    • 8.16.3. Product portfolio 136
    • 8.16.4. Recent initiatives 137
    • 8.17. MediciNova, Inc. 137
    • 8.17.1. Company Overview 137
    • 8.17.2. MediciNova, Inc. Revenue and Gross Margin 137
    • 8.17.3. Product portfolio 138
    • 8.17.4. Recent initiatives 139
    • 8.18. MerLion Pharmaceuticals GmbH 139
    • 8.18.1. Company Overview 139
    • 8.18.2. MerLion Pharmaceuticals GmbH Revenue and Gross Margin 139
    • 8.18.3. Product portfolio 140
    • 8.18.4. Recent initiatives 141
    • 8.19. Mylan N.V. 141
    • 8.19.1. Company Overview 141
    • 8.19.2. Mylan N.V. Revenue and Gross Margin 141
    • 8.19.3. Product portfolio 142
    • 8.19.4. Recent initiatives 143
    • 8.20. Novo Nordisk A/S 143
    • 8.20.1. Company Overview 143
    • 8.20.2. Novo Nordisk A/S Revenue and Gross Margin 143
    • 8.20.3. Product portfolio 144
    • 8.20.4. Recent initiatives 145
    • 8.21. Shionogi Inc. 145
    • 8.21.1. Company Overview 145
    • 8.21.2. Shionogi Inc. Revenue and Gross Margin 145
    • 8.21.3. Product portfolio 146
    • 8.21.4. Recent initiatives 147
    • 8.22. Urigen 147
    • 8.22.1. Company Overview 147
    • 8.22.2. Urigen Revenue and Gross Margin 147
    • 8.22.3. Product portfolio 148
    • 8.22.4. Recent initiatives 149
    • 8.23. Zavante Therapeutics, Inc. 149
    • 8.23.1. Company Overview 149
    • 8.23.2. Zavante Therapeutics, Inc. Revenue and Gross Margin 149
    • 8.23.3. Product portfolio 150
    • 8.23.4. Recent initiatives 151
  •  
  • CHAPTER 9. Urinary Tract Infection Therapeutics — Industry Analysis 152
    • 9.1. Urinary Tract Infection Therapeutics Market – Key Trends 152
    • 9.1.1. Market Drivers 153
    • 9.1.2. Market Restraints 153
    • 9.1.3. Market Opportunities 154
    • 9.2. Value Chain Analysis 155
    • 9.3. Technology Roadmap and Timeline 156
    • 9.4. Urinary Tract Infection Therapeutics Market – Attractiveness Analysis 157
    • 9.4.1. By Age Group 157
    • 9.4.2. By Indication 157
    • 9.4.3. By Drug Type 158
    • 9.4.4. By Distribution Channel 159
    • 9.4.5. By Region  160
  •  
  • CHAPTER 10. Marketing Strategy Analysis, Distributors 161
    • 10.1. Marketing Channel 161
    • 10.2. Direct Marketing 162
    • 10.3. Indirect Marketing 162
    • 10.4. Marketing Channel Development Trend 162
    • 10.5. Economic/Political Environmental Change 163
  •  
  • CHAPTER 11. Report Conclusion 164
  •  
  • CHAPTER 12. Research Approach & Methodology 165
    • 12.1. Report Description 165
    • 12.2. Research Scope 166
    • 12.3. Research Methodology 166
    • 12.3.1. Secondary Research 167
    • 12.3.2. Primary Research 168
    • 12.3.3. Models  169
    • 12.3.3.1. Company Share Analysis Model 169
    • 12.3.3.2. Revenue Based Modeling 170
    • 12.3.3.3. Research Limitations 170

Safe and Secure SSL Encrypted

Choose License Type

INQUIRY FOR BUYING

REQUEST FOR SAMPLE

icon
icon
icon
icon
icon
icon
icon
icon

INQUIRY FOR BUYING

icon
icon
icon
icon
icon
icon
icon
icon
Explore Your Business Market